KR102272671B1 - Glp-1 화합물의 경구 투여 - Google Patents

Glp-1 화합물의 경구 투여 Download PDF

Info

Publication number
KR102272671B1
KR102272671B1 KR1020157032843A KR20157032843A KR102272671B1 KR 102272671 B1 KR102272671 B1 KR 102272671B1 KR 1020157032843 A KR1020157032843 A KR 1020157032843A KR 20157032843 A KR20157032843 A KR 20157032843A KR 102272671 B1 KR102272671 B1 KR 102272671B1
Authority
KR
South Korea
Prior art keywords
peptide
glp
composition
preceding embodiments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157032843A
Other languages
English (en)
Korean (ko)
Other versions
KR20160002945A (ko
Inventor
플레밍 시어 닐센
페르 사우어베르크
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102272671(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Priority to KR1020217020196A priority Critical patent/KR20210086717A/ko
Publication of KR20160002945A publication Critical patent/KR20160002945A/ko
Application granted granted Critical
Publication of KR102272671B1 publication Critical patent/KR102272671B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157032843A 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여 Active KR102272671B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217020196A KR20210086717A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166205.8 2013-05-02
EP13166205 2013-05-02
PCT/EP2014/058974 WO2014177683A1 (en) 2013-05-02 2014-05-02 Oral dosing of glp-1 compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020187029869A Division KR20180115814A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여
KR1020217020196A Division KR20210086717A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여

Publications (2)

Publication Number Publication Date
KR20160002945A KR20160002945A (ko) 2016-01-08
KR102272671B1 true KR102272671B1 (ko) 2021-07-06

Family

ID=48190381

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157032843A Active KR102272671B1 (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여
KR1020187029869A Withdrawn KR20180115814A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여
KR1020217020196A Ceased KR20210086717A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187029869A Withdrawn KR20180115814A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여
KR1020217020196A Ceased KR20210086717A (ko) 2013-05-02 2014-05-02 Glp-1 화합물의 경구 투여

Country Status (25)

Country Link
US (5) US20160067184A1 (enExample)
EP (2) EP2991671B1 (enExample)
JP (2) JP6672140B2 (enExample)
KR (3) KR102272671B1 (enExample)
AU (1) AU2014261336B2 (enExample)
BR (1) BR112015026325A2 (enExample)
CA (1) CA2910903A1 (enExample)
CY (1) CY1120730T1 (enExample)
DK (1) DK2991671T3 (enExample)
ES (1) ES2688462T3 (enExample)
HR (1) HRP20181393T1 (enExample)
HU (1) HUE040609T2 (enExample)
IL (1) IL241813A (enExample)
LT (1) LT2991671T (enExample)
MX (3) MX369259B (enExample)
MY (1) MY172578A (enExample)
PL (1) PL2991671T3 (enExample)
PT (1) PT2991671T (enExample)
RS (1) RS58039B1 (enExample)
RU (1) RU2671406C2 (enExample)
SA (1) SA515370075B1 (enExample)
SI (1) SI2991671T1 (enExample)
SM (1) SMT201800492T1 (enExample)
WO (1) WO2014177683A1 (enExample)
ZA (2) ZA201507096B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250072883A (ko) 2023-11-17 2025-05-26 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2014261336B2 (en) * 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
ES2929218T3 (es) 2015-01-12 2022-11-28 Enteris Biopharma Inc Formas farmacéuticas orales sólidas
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US11196462B2 (en) * 2016-02-22 2021-12-07 Qualcomm Incorporated Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems
EP3474820B1 (en) * 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
KR20200069316A (ko) * 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
MA50047A (fr) * 2017-10-31 2020-07-08 Medimmune Ltd Administration orale d'analogues peptidiques de glp-1
BR112020014624A2 (pt) * 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
ES2993282T3 (en) 2018-07-23 2024-12-26 Lilly Co Eli Method of using a gip/glp1 co-agonist for diabetes
CA3107344A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
JP6920559B2 (ja) 2018-07-23 2021-08-18 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１共アゴニスト化合物
US11471512B2 (en) * 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
TW202214679A (zh) * 2020-07-22 2022-04-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及gip受體共促效劑
CN116157143A (zh) * 2020-07-22 2023-05-23 诺和诺德股份有限公司 适合于口服递送的glp-1和gip受体的共激动剂
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
MX2024000768A (es) 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
US20240294466A1 (en) 2021-07-16 2024-09-05 Novo Nordisk A/S Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
EP4456919A4 (en) * 2021-12-29 2025-10-08 Guangzhou Dazhou Biomedicine Ltd ORAL ADMINISTRATION
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
KR20230132256A (ko) 2022-03-08 2023-09-15 이정열 오징어 조획장치
CN119300864A (zh) 2022-03-31 2025-01-10 美德阿利克斯株式会社 改善了低溶解性和/或低膜渗透性药物的吸收性的制剂
KR20230147981A (ko) 2022-04-15 2023-10-24 이정열 어류 탈취기
KR20230167546A (ko) 2022-06-02 2023-12-11 이정열 어류 탈취기
JPWO2023249087A1 (enExample) 2022-06-24 2023-12-28
KR20240018118A (ko) 2022-08-02 2024-02-13 이정열 어류 탈취기
CA3265745A1 (en) * 2022-08-25 2024-02-29 Univ British Columbia Mucoadhesive pharmaceutical form for the unidirectional release of therapeutic peptidic particles
KR20240055265A (ko) 2022-10-20 2024-04-29 이정열 어류 탈취기
WO2024110614A1 (en) * 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
EP4642440A1 (en) 2022-12-30 2025-11-05 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2025105840A1 (ko) * 2023-11-17 2025-05-22 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
KR20250122090A (ko) 2024-02-06 2025-08-13 이정열 어류 탈취기

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2013009545A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219575A (en) 1986-03-12 1990-04-26 Glaxo Group Ltd Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
PL310897A1 (en) 1993-03-29 1996-01-08 Univ Cincinnati Analogues of yy peptide and their application
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0941114B1 (en) 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
CA2271788A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
CN1311773A (zh) 1998-06-08 2001-09-05 先灵公司 神经肽y5受体拮抗剂
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
SG125915A1 (en) 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2000066629A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
RU2283092C2 (ru) 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
BRPI0412458A (pt) 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
CN101361967A (zh) 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
GB2427550B (en) 2004-03-17 2007-05-30 7Tm Pharma As Y2/Y4 selective receptor agonists for therapeutic interventions
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1750729A2 (en) 2004-05-06 2007-02-14 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
EA013518B1 (ru) 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
CA2565188C (en) 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
CA2573512C (en) 2004-07-12 2014-09-23 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
ES2540929T3 (es) 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
AU2006228525A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AR053495A1 (es) 2005-05-26 2007-05-09 Bristol Myers Squibb Co Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
CA2614619A1 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
WO2007009894A2 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
HRP20150186T1 (hr) 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US7851590B2 (en) 2005-09-21 2010-12-14 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
JP2009508885A (ja) 2005-09-21 2009-03-05 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
US20080255048A1 (en) 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
AU2006324076A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
EP1959987A2 (en) 2005-12-08 2008-08-27 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CA2656019C (en) 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
KR101081149B1 (ko) 2006-09-07 2011-11-07 에미스페어 테크놀로지스, 인코포레이티드 Ｓｎａｃ(살카프로제이트 나트륨)의 제조 방법
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070543A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
BRPI0808517A2 (pt) 2007-03-02 2014-08-19 Novartis Ag Administração oral de uma calcitonina
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
ES2550363T3 (es) 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009040019A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
MX2010011845A (es) 2008-05-16 2010-11-22 Novo Nordisk As Agonistas del receptor y2 y/o y4 de larga accion.
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
ES2375832T3 (es) 2008-10-15 2012-03-06 Bayer Cropscience Ag Uso de ditiin-tetracarboximidas para combatir hongos titopatógenos.
CA2741921A1 (en) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
JP2013505221A (ja) 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
AU2011245980A1 (en) * 2010-04-30 2012-11-08 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
CA2909045C (en) 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2013009545A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250072883A (ko) 2023-11-17 2025-05-26 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 리포좀, 이를 포함하는 약학적 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
CA2910903A1 (en) 2014-11-06
RS58039B1 (sr) 2019-02-28
ZA201806791B (en) 2019-06-26
EP2991671B1 (en) 2018-08-15
DK2991671T3 (en) 2018-10-08
IL241813A (en) 2017-12-31
ES2688462T3 (es) 2018-11-02
EP3485900A1 (en) 2019-05-22
JP6672140B2 (ja) 2020-03-25
PT2991671T (pt) 2018-11-05
US20250262159A1 (en) 2025-08-21
ZA201507096B (en) 2020-01-29
AU2014261336A1 (en) 2015-10-08
US20170312225A1 (en) 2017-11-02
JP2016519128A (ja) 2016-06-30
US12239739B2 (en) 2025-03-04
MX2018012166A (es) 2020-09-02
US20190216739A1 (en) 2019-07-18
AU2014261336B2 (en) 2019-02-28
SI2991671T1 (sl) 2018-10-30
MX369259B (es) 2019-11-04
KR20210086717A (ko) 2021-07-08
HUE040609T2 (hu) 2019-03-28
CY1120730T1 (el) 2019-12-11
HRP20181393T1 (hr) 2018-11-02
BR112015026325A2 (pt) 2017-07-25
JP7576910B2 (ja) 2024-11-01
SA515370075B1 (ar) 2017-08-27
PL2991671T3 (pl) 2019-01-31
US10278923B2 (en) 2019-05-07
KR20180115814A (ko) 2018-10-23
RU2671406C2 (ru) 2018-10-31
RU2015147876A (ru) 2017-06-06
EP2991671A1 (en) 2016-03-09
MX2015015009A (es) 2016-03-09
WO2014177683A1 (en) 2014-11-06
LT2991671T (lt) 2018-09-25
MX2019013123A (es) 2019-12-05
JP2020073533A (ja) 2020-05-14
KR20160002945A (ko) 2016-01-08
SMT201800492T1 (it) 2018-11-09
US20250213485A1 (en) 2025-07-03
US20160067184A1 (en) 2016-03-10
MY172578A (en) 2019-12-03

Similar Documents

Publication Publication Date Title
KR102272671B1 (ko) Glp-1 화합물의 경구 투여
TWI804571B (zh) 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
TWI829687B (zh) 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
US20250195618A1 (en) Compositions of glp-1 peptides and preparation thereof
RU2600440C2 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(2-гидроксибензоил)амино)каприловой кислоты
EP3634468B1 (en) Solid compositions for oral administration
CN115461044B (zh) 包含glp-1激动剂和组氨酸的固体组合物
KR20220044269A (ko) Glp-1 작용제, sglt2 억제제, 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형분 조성물
KR20200013078A (ko) Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
HK40017148B (en) Solid compositions for oral administration
HK40017148A (en) Solid compositions for oral administration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181016

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200901

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210326

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200901

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210326

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201029

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210504

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210427

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210326

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20201029

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210629

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210629

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 4

End annual number: 4